Directs the department of health to report to the legislature on the feasibility of entering into partnerships to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers, and consumers, and to increase patient access to affordable drugs; makes related provisions.
STATE OF NEW YORK
________________________________________________________________________
8345--B
2023-2024 Regular Sessions
IN ASSEMBLY
December 13, 2023
___________
Introduced by M. of A. RAJKUMAR, L. ROSENTHAL, SEAWRIGHT -- read once
and referred to the Committee on Health -- recommitted to the Commit-
tee on Health in accordance with Assembly Rule 3, sec. 2 -- committee
discharged, bill amended, ordered reprinted as amended and recommitted
to said committee -- again reported from said committee with amend-
ments, ordered reprinted as amended and recommitted to said committee
AN ACT in relation to requiring the department of health to report on
the feasibility of establishing a generic drug manufacturing program
aimed at reducing the cost of prescription drugs and to address short-
ages in the market for generic prescription drugs
The People of the State of New York, represented in Senate and Assem-bly, do enact as follows:
1 Section 1. On or before January first, two thousand twenty-six, the
2 department of health shall submit a report to the legislature that
3 assesses the feasibility of establishing a generic drug manufacturing
4 program aimed at reducing the cost of prescription drugs and to address
5 shortages in the market for generic prescription drugs by directly manu-
6 facturing generic prescription drugs and selling generic prescription
7 drugs at a fair price. The report shall conduct an analysis of gover-
8 nance structure options for manufacturing functions, including charter-
9 ing a private organization, a public-private partnership, or a public
10 board of directors. Additionally, the report shall include, but not be
11 limited to an analysis of the:
12 (a) feasibility of entering into a partnership with a drug manufactur-
13 er to produce insulin and generic drugs for chronic and high-cost condi-
14 tions;
15 (b) feasibility of entering into a partnership with a drug manufactur-
16 er to produce and make generic prescription drugs widely available;
17 (c) generic prescription drugs that would have the greatest impact on
18 lowering drug costs to patients, including high-cost drugs, high utili-
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[] is old law to be omitted.
LBD08090-04-4
A. 8345--B 2
1 zation drugs, or drugs experiencing shortages in the market which the
2 program may prioritize;
3 (d) amount of staff required to oversee and manage the partnerships
4 for manufacturing or distribution of generic prescription drugs;
5 (e) research and development costs and start up costs associated with
6 the generic drug manufacturing program; and
7 (f) volume of generic prescription drugs and insulin that can be
8 produced over the first five years of the program.
9 § 2. This act shall take effect on the first of January next succeed-
10 ing one year after it shall have become a law.
